Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) was presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"Patients with CDI often have persistent infections or develop new infections during the course of CDI treatment and are often administered concomitant antibiotics. Although clinically necessary the use of concomitant antibiotics has a deleterious effect on outcomes of cure, recurrence and global cure. Compared to vancomycin therapy, fidaxomicin blunts these negative effects by significantly lowering recurrences and increasing global cure of patients," said Pedro Lichtinger, Optimer's President and Chief Executive Officer.  "The additional data presented suggest fidaxomicin has the potential to become the product of choice for CDI, if approved."

Kathleen M. Mullane, D.O., Pharm. D., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented combined data from Optimer's two Phase 3 trials indicating that the use of concomitant antibiotics is a significant risk factor for a negative CDI treatment outcome.  Many patients with CDI have persistent infections or develop new infections during the course of CDI treatment making concomitant antibiotics clinically necessary and common.  Overall, 34% of subjects received antibiotics in addition to fidaxomicin a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Shimadzu Scientific Instruments will showcase several ... and marijuana analysis at the Pittcon 2015 conference and ... at the Ernest N. Morial Convention Center in New ... 3121 to discuss laboratory challenges with Shimadzu’s technical experts ... help save time, money and effort in the lab. ...
(Date:3/2/2015)... York, NY (PRWEB) March 02, 2015 ... Testing Services industry has experienced robust growth. The ... consumer products, industrial materials, energy resources and other goods, ... and rising government regulation. As a result, IBISWorld forecasts ... of 2.8% to reach $946.8 million over the five-year ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Resilinc ... annual report which summarizes and analyzes nearly ... its EventWatch™ 24X7 global event monitoring and ... subscribe to a free trial period of the email ... chain incidents that can negatively impact revenue, market share, ...
(Date:3/2/2015)... , March 2, 2015 Analyzing a ... have identified a new syndrome, shedding light on ... also provides important information to help caregivers manage ... treating it. "This syndrome illuminates a ... of master switch that controls many other genes," ...
Breaking Biology Technology:Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 2Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 2New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 4
... LLC of Irvine, California today announced a strategic ... CompanDX have forged a unique partnership to offer ... molecular diagnostic tests for clients in the healthcare ... deliver small composite biomarker signatures from complex data ...
... BOTHELL, Wash., June 16, 2011 SCOLR Pharma, Inc. ... sale of $1 million principal amount of its 8% ... an initial closing of its private offering of up ... may offer additional Debentures, up to the aggregate maximum ...
... , -- " Ask,Extractor ... " Help Researchers Narrow Search Results,-- ... information products and services, today announced two new,applications from Molecular ... Ask Extractor is an application based on Molecular ...
Cached Biology Technology:ResearchDx and CompanDX Announce Strategic Partnership 2SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 2SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 3Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications 2Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications 3Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications 4Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications 5Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications 6
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Singh Malik, Ph.D., of Fred Hutchinson Cancer Research Center, ... Institute to study the potential role of "genetic conflicts" ... Malik and colleagues want to find out whether a ... to determine whether autoimmunity when the body,s immune ...
... , ,A Griffith University PhD candidate has been highly awarded ... atom. Ben Norton, from the Kielpinski group in ... CiSRA Extreme Imaging Competition following extensive work on high resolution ... Inc.,s Australian research centre, the Extreme Imaging competition aims to ...
... is available in French . Vancouver, B.C. -- ... place at the wrong time. As a result of changing conditions, marine ... as three kilometres per year over the past 50 years, and forecasts ... years. Decisions on where to put MPAs weren,t always made with ...
Cached Biology News:Did an evolutionary arms race cause lupus? Biologist Harmit Malik receives grant to try and find out 2Extreme imaging wins science praise 2Marine protected areas: changing climate could require change of plans 2
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Prepared in distilled water....
... Weight Markers, 37 kBq, 1 uCi. Carbon-14 ... of the sample on Western blots.The Rainbow-labeled ... migration in the gel and on the ... without Rainbow-labeling is 0.37-3.7 MBq/mg (10-100 uCi/mg) ...
in vitro Translation, Accessory Products...
Biology Products: